Navigation Links
Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice
Date:2/6/2008

Research by March of Dimes Grantee Offers Hope for Treatment of Children

WHITE PLAINS, N.Y., Feb. 6 /PRNewswire-USNewswire/ -- A new gene-based technique has successfully prevented a rare craniofacial birth defect in mice and holds promise to help children with the same disorder, according to new research funded in part by the March of Dimes.

The finding, which is being published in the journal Nature Medicine, demonstrates the potential for translating basic research into new treatments, said Michael Katz, M.D., senior vice president for Research and Global Programs at the March of Dimes.

Paul A. Trainor, Ph.D., a March of Dimes research grantee, and a team of scientists at the Stowers Institute for Medical Research in Kansas City, Missouri, demonstrated that they could prevent Treacher Collins syndrome (TCS) in mice by either inactivating a gene associated with the disorder or by inhibiting a protein produced by the gene.

In TCS, mutations in the TCOF1 gene on chromosome 5 causes a high degree of cell death in the embryo, resulting in a deficiency in a cell population called the neural crest that is essential for generating most of the bone and cartilage that make up the head and face. Dr. Trainor's team showed in 2006 that the loss of these cells results in abnormal embryonic development of structures such as the ear, nose, palate, and upper and lower jaws.

About one in 50,000 people is affected by TCS, also called mandibulofacial dysostosis. The condition is characterized by underdeveloped, malformed, or missing facial structures. Severely affected children often require multiple reconstructive surgeries, which may not fully correct the disorder.

In about 60 percent of cases, TCS results from new gene mutations and occurs in people with no history of the disorder in their family. Less frequently, TCS is inherited in an autosomal dominant pattern, meaning that one parent has the disorder and has passed
'/>"/>

SOURCE March of Dimes
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery
2. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
4. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
5. Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
8. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
9. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
10. Molecular Biometrics Hires Denny Sakkas, PhD Renowned Yale Embryologist and International Thought-Leader, as Chief Scientific Officer; Opening U.S. Research Facility
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...inker.comannouncesthatanewmarketresearchreportisav...ry-USMarketTrends&Analysis http://www.reportl...arket-Trends--Analysis.html ,, TheUSintranasal...uticapplicationsfromthedeliveryofconventionallocal...drugs.Thefutureofthetechnologyhingesontotheeffecti...
(Date:11/25/2009)...re/-- ChemoCentryx,Inc.,announcedtodaythatPhaseII...ectiveRandomizedOralTherapyEvaluationinCrohn,sdise...moderate-to-severeCrohn,sdiseasedemonstratedclinic...le.Thestudydemonstratedevidenceofclinicalefficacyi...decreaseintheCrohn,sDiseaseActivityIndex(CDAI)inpa...
(Date:11/24/2009)...stCall/--Endologix,Inc.(Nasdaq: ELGX ),developerof...uncedtodaythatithasfiledamotiontostay,ordiscontinu...ghtagainstitinOctober2009byCook,Inc.Themotionwasfi...diana. ,, Endologixhasrequestedthatthestayremai...ice(USPTO)conductsproceedingstore-examinethetwopat...
Breaking Medicine Technology:Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 1Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 2Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 3National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 1National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 2National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 3National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 4National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 5Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 1Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 2Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 3Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 4Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 5Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 6Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 7Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 8Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 9Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 10
...linical program to evaluate PROMUS(TM) Element(TM)...3 Boston Scientific Corporation (NYSE: BSX ) to...in the PLATINUM clinical trial, which is designed ...verolimus-Eluting Coronary Stent. The first U.S. ...er of the Rockies in Loveland, Colorado by Thomas ...
...NG-WEIHENSTEPHAN, Germany, February 3 Pieris AG, ...R), a novel class of targeted,human protein therap...,progress in the development of its Anticalin(R) c...oad therapeutic applicability. , Having succes...in vitro,and in vivo, Pieris has now validated the...
Other Medicine Technology:Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 2Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 3Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 4Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 5Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist 2Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist 3
(Date:11/27/2009)... Holdings has announced that it has become a natio...e largest nonprofit organizations dedicated to art... Delray Beach, FL (Vocus) Nov...XCHO), a company specializing in the marketing and...ts, has announced today that is has become a natio...
(Date:11/27/2009)...ealth™ announced today that Spectrum Health ...d Enterprise orthopedic templating solution and it... (PRWEB) November 27, 2009 -- Voyant...h (Grand Rapids, Michigan) has licensed its Trauma...its TraumaCad Extend workflow solution, to allow i...
(Date:11/26/2009)...--Withcoldandfluseasonuponus,it,smoreimportantthan...tionsandavoidillness. ,, "Weneedtobeproactiveno...illnessifwe,resick,"saidEileenFinerty,RN,MS,CIC(ce...ctioncontrolandoccupationalhealthatHospitalforSpec...alSurgeryhasoneofthelowestinfectionratesofanyhospi...
(Date:11/26/2009)...y can lead to strains or worse , , THURS...ing wrong with stuffing your turkey full to bursti...th your suitcase as you pack for holiday trips. ,... U.S. hospital emergency rooms, doctors, offices, ...elated injuries, such as muscle strains, pulls and...
(Date:11/26/2009)... Triangle Dental (RTDental), a leading dental grou...ced the expansion of its services to include LUMIN...millan. , Durham, NC (...nnounce that Dr. Doug Macmillan, an experienced L...l advanced training seminar. RTDental’s abi...
Breaking Medicine News(10 mins):Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2
...Food and Drug Administration (FDA) today announced...and Factor Complex (Human), Alphanate. //The produ...invasive procedures with von Willebrand disease (v...oing major surgery. The disease is the most common...
...m (Tamil Nadu): Over 3,000 transsexuals in Tamil N...hat society will now "see" them differently.// ...n AIDS awareness campaigner from Vellore and pledg...ervices. The mass eye donation by the 'arav...
...s have found more than 250 species of bacteria dw...animal //species in a zoo, which prompts lead rese...acteria out there on the human body. Stating t...er says he was astounded by results of his work, w...
..., a drug used for limiting blood loss in patients ...increased risk of death during five years followin...rotinin was first approved for use in high-risk pa...ion patients worldwide have received aprotinin sin...
...y published in Clinical Pediatrics, it is reported...itamin D. If this deficit is taken care of, their ...ency disorders. Joyce M. Lee and his team belo...nd to be deficient in vitamin D. Among their child...
...rs have found that wisdom in old age depends on a ...researchers found that when mature mice learn a ne...e times more active than their old ones, the New S...roup of mice with a chemical agent that stains onl...
Other Medicine News:Health News:FDA Approves New Product to Treat Von Willebrand Disease 2Health News:The Other Side of Transsexuals 2Health News:Unknown Species of Bacteria Among a ‘zoo’ of Them on the Human Bo 2Health News:Drug Used in Coronary Artery Bypass Surgery may Increase Risk of Death 2
IMMULITE/IMMULITE 1000 Cortisol
...ors from KUBTEC represents a stand-alone, high-res...to 16 bit digital interface. The large sensing are... spacing down to 48 microns. All models are availa...ed energy range (10-160 kV). Applications range fr...
...UBTEC is a dual capability system with the ability...on of the specimen under test. While the XCAT seri...X-ray images, the micro focus source also allows t...ard 2D images. The 100 mm x 100 mm digital detecto...
...men radiography. The XPERT represents a research t...n every digital x-ray image, thus being able to ca...ore were lost to the human eye. With features incl...e, multi-color digital operator interface, and a 1...
Medicine Products: